SPOTLIGHT: Encysive fails to satisfy FDA

Shares of Encysive Pharmaceuticals slipped after the FDA announced that the developer's response to its July 24 approvable letter for Thelin was incomplete. Encysive said that it can get the FDA the additional information it needs in a few days. Report

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.